Posted by Michael Wonder on 23 Jan 2024
4DMT receives rare paediatric disease designation from FDA for aerosolised 4D-710 for treatment of cystic fibrosis lung disease
23 January 2024 - Interim data update from Phase 1/2 AEROW clinical trial expected in mid-2024, and pivotal trial planning update expected in Q1.
4D Molecular Therapeutics today announced that the US FDA has granted rare paediatric disease designation for the Company’s product candidate aerosolised 4D-710 for treatment of cystic fibrosis lung disease.
